文献速递前列腺癌

欧洲前列腺癌筛查成本效果的系统评价

Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe.
PubMed 文献 · Eur Urol · 2024-05-23

该系统评价检索四个数据库,共纳入19项欧洲经济评价研究,分析前列腺癌筛查的成本效果。基于风险分层和/或年龄和/或磁共振成像(MRI)联合前列腺特异性抗原(PSA)检测的筛查策略,与不筛查相比,增量成本效果比(ICER)从每质量调整生命年(QALY)5872欧元至372948欧元不等,中位数为56487欧元/QALY。基于风险的筛查联合MRI似乎比不筛查更具成本效果。

要点

  • 共纳入19项欧洲经济评价研究,评估前列腺癌筛查的成本效果。
  • 基于风险分层和/或年龄和/或MRI联合PSA检测的筛查策略,ICER范围为每QALY 5872至372948欧元,中位数56487欧元/QALY。
  • 基于风险的筛查联合MRI似乎比不筛查更具成本效果。

核心结论

  • 系统评价表明,纳入基于风险的方法和MRI的筛查方案具有成本效果的潜力。
  • 关于前列腺癌筛查成本效果仍存在知识空白,成本效果的决定因素需进一步研究。

研究设计与样本

  • 采用PICO方法进行同行评议文献检索,在四个数据库中制定详细检索策略,关键词包括前列腺癌、筛查和成本效果。
  • 纳入任何类型的经济评价,检索策略限制于欧洲国家,发表年份不限。
  • 最初识别7484项研究,最终19项研究描述了欧洲前列腺癌筛查的成本效果。

主要发现

  • 在初始健康研究人群中,多数研究关注基于风险和/或年龄和/或MRI的筛查联合PSA检测,并与不筛查进行比较。
  • 增量成本效果比(ICER)从每QALY 5872欧元至372948欧元不等,中位数为56487欧元/QALY。
  • 基于风险的筛查联合MRI似乎比不筛查更具成本效果。

关键数值与推荐

  • ICER范围:每QALY 5872欧元至372948欧元,中位数56487欧元/QALY,对应基于风险和/或年龄和/或MRI的筛查联合PSA检测与不筛查的比较。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 关于前列腺癌筛查成本效果仍存在知识空白。
  • 成本效果的决定因素需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In Europe, prostate cancer (PCa) is the most common cancer in men. Screening may therefore be crucial to lower health care costs, morbidity, and mortality. This systematic review aimed to provide a contemporary overview of the costs and benefits of PCa screening programmes. METHODS: A peer-reviewed literature search was conducted, using the PICO method. A detailed search strategy was developed in four databases based on the following key search terms: "PCa", "screening", and "cost effectiveness". Any type of economic evaluation was included. The search strategy was restricted to European countries, but no restrictions were set on the year of publication. KEY FINDINGS AND LIMITATIONS: A total of 7484 studies were identified initially. Of these, 19 studies described the cost effectiveness of PCa screening in Europe. Among the studies using an initially healthy study population, most focussed on risk- and/or age- and/or magnetic resonance imaging (MRI)-based screening in addition to prostate-specific antigen (PSA) testing and compared this with no screening. Incremental cost ratios (ICERs) varied from €5872 per quality-adjusted life year (QALY) to €372 948/QALY, with a median of €56 487/QALY. Risk-based screening followed by MRI testing seemed to be a more cost-effective strategy than no screening. CONCLUSIONS AND CLINICAL IMPLICATIONS: This systematic review indicates that screening programmes incorporating a risk-based approach and MRI have the potential to be cost effective. PATIENT SUMMARY: In this review, we looked at the cost effectiveness of prostate cancer screening in Europe. We found that a risk-based approach and incorporation of magnetic resonance imaging has the potential to be cost effective. However, there remains a knowledge gap regarding cost effectiveness of prostate cancer screening. Therefore, determinants of cost effectiveness require further investigation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Vynckier P, Annemans L, Raes S, et al. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe. Eur Urol. 2024. PMID: 38789306. doi:10.1016/j.eururo.2024.04.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。